Biologic
RCSB PDB 1RHG
Filgrastim
Neupogen
- Mechanism of action
- G-CSF receptor agonist
- In plain language
- A lab-made copy of a natural body signal that tells the bone marrow to produce more infection-fighting white blood cells.
- How it works
- Filgrastim is a recombinant form of human granulocyte colony-stimulating factor (G-CSF) that acts on specific cell surface receptors on hematopoietic cells to regulate neutrophil production in the bone marrow. It stimulates the proliferation, differentiation, and functional activation of neutrophil progenitors — including enhanced phagocytic ability and increased cell surface antigen expression on mature neutrophils — with the FDA label noting minimal direct effect on other hematopoietic cell lineages. This lineage-selective action raises circulating neutrophil counts without broadly stimulating the rest of the blood cell-producing system.
- Therapeutic applications
- Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs; to reduce time to neutrophil recovery and duration of fever following induction or consolidation chemotherapy in acute myeloid leukemia; to reduce the duration of neutropenia and related complications in patients undergoing myeloablative chemotherapy followed by bone marrow transplant; to mobilize autologous hematopoietic progenitor cells into peripheral blood for collection by leukapheresis; for chronic administration to reduce infection incidence in patients with severe chronic neutropenia; and to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
- Class
- Peptide analog
- Therapeutic area
- Hematology
View
Related compounds